News - Page 241 - Psychedelic Alpha

Our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.

Read more about the article Lobe Sciences Commences Engineering of Nasal Mist Device

Lobe Sciences Commences Engineering of Nasal Mist Device

Post published:December 3, 2020
Post category:Press Release

Read more about the article Epidemiologist Dr. Joel Moody Joins Revive Therapeutics as Medical and Clinical Advisor

Epidemiologist Dr. Joel Moody Joins Revive Therapeutics as Medical and Clinical Advisor

Post published:December 2, 2020
Post category:Press Release

Read more about the article Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide (“LSD”) to Treat Parkinson’s Disease

Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide (“LSD”) to Treat Parkinson’s Disease

Post published:December 2, 2020
Post category:Press Release

Read more about the article Pure Extracts Collaborates with Dr. Alexander MacGregor on Cannabis and Mushroom Formulations

Pure Extracts Collaborates with Dr. Alexander MacGregor on Cannabis and Mushroom Formulations

Post published:December 2, 2020
Post category:Press Release

Read more about the article Numinus and MAPS Public Benefit Corporation announce collaboration agreement to seek approval of MDMA-assisted psychotherapy for PTSD single-arm, open-label trial

Numinus and MAPS Public Benefit Corporation announce collaboration agreement to seek approval of MDMA-assisted psychotherapy for PTSD single-arm, open-label trial

Post published:December 2, 2020
Post category:Press Release

Read more about the article Havn Life Attracts International Drug Science and Policy Expert, Joins UK Policy Reform Group

Havn Life Attracts International Drug Science and Policy Expert, Joins UK Policy Reform Group

Post published:December 2, 2020
Post category:Press Release

Read more about the article Mind Cure Announces Eligibility for DTC Trading

Mind Cure Announces Eligibility for DTC Trading

Post published:December 2, 2020
Post category:Press Release

Read more about the article Mind Cure Promotes Kelsey Ramsden to President and Chief Executive Officer

Mind Cure Promotes Kelsey Ramsden to President and Chief Executive Officer

Post published:December 1, 2020
Post category:Press Release

Read more about the article CaaMTech Collaborates With the Leibniz Institute for Natural Product Research to Investigate Psychedelic Mushrooms

CaaMTech Collaborates With the Leibniz Institute for Natural Product Research to Investigate Psychedelic Mushrooms

Post published:December 1, 2020
Post category:Press Release

Read more about the article Entheon Biomedical Announces CRO Agreement with CHDR for Phase 1 Clinical Trial; Centre for Human Drug Research Led DMT Study to Start in 2021

Entheon Biomedical Announces CRO Agreement with CHDR for Phase 1 Clinical Trial; Centre for Human Drug Research Led DMT Study to Start in 2021

Post published:December 1, 2020
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.